Global Subcutaneous Injectable Suspensions Market Growth (Status and Outlook) 2023-2029
LPI (LP Information)' newest research report, the “Subcutaneous Injectable Suspensions Industry Forecast” looks at past sales and reviews total world Subcutaneous Injectable Suspensions sales in 2022, providing a comprehensive analysis by region and market sector of projected Subcutaneous Injectable Suspensions sales for 2023 through 2029. With Subcutaneous Injectable Suspensions sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Subcutaneous Injectable Suspensions industry.
This Insight Report provides a comprehensive analysis of the global Subcutaneous Injectable Suspensions landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Subcutaneous Injectable Suspensions portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Subcutaneous Injectable Suspensions market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Subcutaneous Injectable Suspensions and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Subcutaneous Injectable Suspensions.
The global Subcutaneous Injectable Suspensions market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Subcutaneous Injectable Suspensions is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Subcutaneous Injectable Suspensions is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Subcutaneous Injectable Suspensions is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Subcutaneous Injectable Suspensions players cover Merck Sharp & Dohme, Novo Nordisk, Lilly, Biocon Limited, Pfizer, BeiGene, EnteraBio, AbbVie and Pfizer Limited, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Subcutaneous Injectable Suspensions market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Single-Dose Injections
Multiple-Dose Injections
Segmentation by application
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck Sharp & Dohme
Novo Nordisk
Lilly
Biocon Limited
Pfizer
BeiGene
EnteraBio
AbbVie
Pfizer Limited
Teva Pharmaceuticals USA
Bristol-Myers Squibb
Cipla
Baxter International
AstraZeneca
Please note: The report will take approximately 2 business days to prepare and deliver.
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Subcutaneous Injectable Suspensions Market Size 2018-2029
- 2.1.2 Subcutaneous Injectable Suspensions Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Subcutaneous Injectable Suspensions Segment by Type
- 2.2.1 Single-Dose Injections
- 2.2.2 Multiple-Dose Injections
- 2.3 Subcutaneous Injectable Suspensions Market Size by Type
- 2.3.1 Subcutaneous Injectable Suspensions Market Size CAGR by Type (2018 VS 2022 VS 2029)
- 2.3.2 Global Subcutaneous Injectable Suspensions Market Size Market Share by Type (2018-2023)
- 2.4 Subcutaneous Injectable Suspensions Segment by Application
- 2.4.1 Hospitals Pharmacies
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Pharmacies
- 2.5 Subcutaneous Injectable Suspensions Market Size by Application
- 2.5.1 Subcutaneous Injectable Suspensions Market Size CAGR by Application (2018 VS 2022 VS 2029)
- 2.5.2 Global Subcutaneous Injectable Suspensions Market Size Market Share by Application (2018-2023)
- 3 Subcutaneous Injectable Suspensions Market Size by Player
- 3.1 Subcutaneous Injectable Suspensions Market Size Market Share by Players
- 3.1.1 Global Subcutaneous Injectable Suspensions Revenue by Players (2018-2023)
- 3.1.2 Global Subcutaneous Injectable Suspensions Revenue Market Share by Players (2018-2023)
- 3.2 Global Subcutaneous Injectable Suspensions Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
- 4 Subcutaneous Injectable Suspensions by Regions
- 4.1 Subcutaneous Injectable Suspensions Market Size by Regions (2018-2023)
- 4.2 Americas Subcutaneous Injectable Suspensions Market Size Growth (2018-2023)
- 4.3 APAC Subcutaneous Injectable Suspensions Market Size Growth (2018-2023)
- 4.4 Europe Subcutaneous Injectable Suspensions Market Size Growth (2018-2023)
- 4.5 Middle East & Africa Subcutaneous Injectable Suspensions Market Size Growth (2018-2023)
- 5 Americas
- 5.1 Americas Subcutaneous Injectable Suspensions Market Size by Country (2018-2023)
- 5.2 Americas Subcutaneous Injectable Suspensions Market Size by Type (2018-2023)
- 5.3 Americas Subcutaneous Injectable Suspensions Market Size by Application (2018-2023)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Subcutaneous Injectable Suspensions Market Size by Region (2018-2023)
- 6.2 APAC Subcutaneous Injectable Suspensions Market Size by Type (2018-2023)
- 6.3 APAC Subcutaneous Injectable Suspensions Market Size by Application (2018-2023)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 7 Europe
- 7.1 Europe Subcutaneous Injectable Suspensions by Country (2018-2023)
- 7.2 Europe Subcutaneous Injectable Suspensions Market Size by Type (2018-2023)
- 7.3 Europe Subcutaneous Injectable Suspensions Market Size by Application (2018-2023)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Subcutaneous Injectable Suspensions by Region (2018-2023)
- 8.2 Middle East & Africa Subcutaneous Injectable Suspensions Market Size by Type (2018-2023)
- 8.3 Middle East & Africa Subcutaneous Injectable Suspensions Market Size by Application (2018-2023)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Global Subcutaneous Injectable Suspensions Market Forecast
- 10.1 Global Subcutaneous Injectable Suspensions Forecast by Regions (2024-2029)
- 10.1.1 Global Subcutaneous Injectable Suspensions Forecast by Regions (2024-2029)
- 10.1.2 Americas Subcutaneous Injectable Suspensions Forecast
- 10.1.3 APAC Subcutaneous Injectable Suspensions Forecast
- 10.1.4 Europe Subcutaneous Injectable Suspensions Forecast
- 10.1.5 Middle East & Africa Subcutaneous Injectable Suspensions Forecast
- 10.2 Americas Subcutaneous Injectable Suspensions Forecast by Country (2024-2029)
- 10.2.1 United States Subcutaneous Injectable Suspensions Market Forecast
- 10.2.2 Canada Subcutaneous Injectable Suspensions Market Forecast
- 10.2.3 Mexico Subcutaneous Injectable Suspensions Market Forecast
- 10.2.4 Brazil Subcutaneous Injectable Suspensions Market Forecast
- 10.3 APAC Subcutaneous Injectable Suspensions Forecast by Region (2024-2029)
- 10.3.1 China Subcutaneous Injectable Suspensions Market Forecast
- 10.3.2 Japan Subcutaneous Injectable Suspensions Market Forecast
- 10.3.3 Korea Subcutaneous Injectable Suspensions Market Forecast
- 10.3.4 Southeast Asia Subcutaneous Injectable Suspensions Market Forecast
- 10.3.5 India Subcutaneous Injectable Suspensions Market Forecast
- 10.3.6 Australia Subcutaneous Injectable Suspensions Market Forecast
- 10.4 Europe Subcutaneous Injectable Suspensions Forecast by Country (2024-2029)
- 10.4.1 Germany Subcutaneous Injectable Suspensions Market Forecast
- 10.4.2 France Subcutaneous Injectable Suspensions Market Forecast
- 10.4.3 UK Subcutaneous Injectable Suspensions Market Forecast
- 10.4.4 Italy Subcutaneous Injectable Suspensions Market Forecast
- 10.4.5 Russia Subcutaneous Injectable Suspensions Market Forecast
- 10.5 Middle East & Africa Subcutaneous Injectable Suspensions Forecast by Region (2024-2029)
- 10.5.1 Egypt Subcutaneous Injectable Suspensions Market Forecast
- 10.5.2 South Africa Subcutaneous Injectable Suspensions Market Forecast
- 10.5.3 Israel Subcutaneous Injectable Suspensions Market Forecast
- 10.5.4 Turkey Subcutaneous Injectable Suspensions Market Forecast
- 10.5.5 GCC Countries Subcutaneous Injectable Suspensions Market Forecast
- 10.6 Global Subcutaneous Injectable Suspensions Forecast by Type (2024-2029)
- 10.7 Global Subcutaneous Injectable Suspensions Forecast by Application (2024-2029)
- 11 Key Players Analysis
- 11.1 Merck Sharp & Dohme
- 11.1.1 Merck Sharp & Dohme Company Information
- 11.1.2 Merck Sharp & Dohme Subcutaneous Injectable Suspensions Product Offered
- 11.1.3 Merck Sharp & Dohme Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 Merck Sharp & Dohme Main Business Overview
- 11.1.5 Merck Sharp & Dohme Latest Developments
- 11.2 Novo Nordisk
- 11.2.1 Novo Nordisk Company Information
- 11.2.2 Novo Nordisk Subcutaneous Injectable Suspensions Product Offered
- 11.2.3 Novo Nordisk Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.2.4 Novo Nordisk Main Business Overview
- 11.2.5 Novo Nordisk Latest Developments
- 11.3 Lilly
- 11.3.1 Lilly Company Information
- 11.3.2 Lilly Subcutaneous Injectable Suspensions Product Offered
- 11.3.3 Lilly Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.3.4 Lilly Main Business Overview
- 11.3.5 Lilly Latest Developments
- 11.4 Biocon Limited
- 11.4.1 Biocon Limited Company Information
- 11.4.2 Biocon Limited Subcutaneous Injectable Suspensions Product Offered
- 11.4.3 Biocon Limited Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.4.4 Biocon Limited Main Business Overview
- 11.4.5 Biocon Limited Latest Developments
- 11.5 Pfizer
- 11.5.1 Pfizer Company Information
- 11.5.2 Pfizer Subcutaneous Injectable Suspensions Product Offered
- 11.5.3 Pfizer Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.5.4 Pfizer Main Business Overview
- 11.5.5 Pfizer Latest Developments
- 11.6 BeiGene
- 11.6.1 BeiGene Company Information
- 11.6.2 BeiGene Subcutaneous Injectable Suspensions Product Offered
- 11.6.3 BeiGene Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.6.4 BeiGene Main Business Overview
- 11.6.5 BeiGene Latest Developments
- 11.7 EnteraBio
- 11.7.1 EnteraBio Company Information
- 11.7.2 EnteraBio Subcutaneous Injectable Suspensions Product Offered
- 11.7.3 EnteraBio Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.7.4 EnteraBio Main Business Overview
- 11.7.5 EnteraBio Latest Developments
- 11.8 AbbVie
- 11.8.1 AbbVie Company Information
- 11.8.2 AbbVie Subcutaneous Injectable Suspensions Product Offered
- 11.8.3 AbbVie Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.8.4 AbbVie Main Business Overview
- 11.8.5 AbbVie Latest Developments
- 11.9 Pfizer Limited
- 11.9.1 Pfizer Limited Company Information
- 11.9.2 Pfizer Limited Subcutaneous Injectable Suspensions Product Offered
- 11.9.3 Pfizer Limited Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.9.4 Pfizer Limited Main Business Overview
- 11.9.5 Pfizer Limited Latest Developments
- 11.10 Teva Pharmaceuticals USA
- 11.10.1 Teva Pharmaceuticals USA Company Information
- 11.10.2 Teva Pharmaceuticals USA Subcutaneous Injectable Suspensions Product Offered
- 11.10.3 Teva Pharmaceuticals USA Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.10.4 Teva Pharmaceuticals USA Main Business Overview
- 11.10.5 Teva Pharmaceuticals USA Latest Developments
- 11.11 Bristol-Myers Squibb
- 11.11.1 Bristol-Myers Squibb Company Information
- 11.11.2 Bristol-Myers Squibb Subcutaneous Injectable Suspensions Product Offered
- 11.11.3 Bristol-Myers Squibb Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.11.4 Bristol-Myers Squibb Main Business Overview
- 11.11.5 Bristol-Myers Squibb Latest Developments
- 11.12 Cipla
- 11.12.1 Cipla Company Information
- 11.12.2 Cipla Subcutaneous Injectable Suspensions Product Offered
- 11.12.3 Cipla Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.12.4 Cipla Main Business Overview
- 11.12.5 Cipla Latest Developments
- 11.13 Baxter International
- 11.13.1 Baxter International Company Information
- 11.13.2 Baxter International Subcutaneous Injectable Suspensions Product Offered
- 11.13.3 Baxter International Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.13.4 Baxter International Main Business Overview
- 11.13.5 Baxter International Latest Developments
- 11.14 AstraZeneca
- 11.14.1 AstraZeneca Company Information
- 11.14.2 AstraZeneca Subcutaneous Injectable Suspensions Product Offered
- 11.14.3 AstraZeneca Subcutaneous Injectable Suspensions Revenue, Gross Margin and Market Share (2018-2023)
- 11.14.4 AstraZeneca Main Business Overview
- 11.14.5 AstraZeneca Latest Developments
- 12 Research Findings and Conclusion
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook